vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and TEXAS CAPITAL BANCSHARES INC (TCBI). Click either name above to swap in a different company.
TEXAS CAPITAL BANCSHARES INC is the larger business by last-quarter revenue ($324.0M vs $168.4M, roughly 1.9× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 15.5%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 10.2%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Texas Capital Bank is a bank headquartered in Dallas, Texas. The bank has branches located in every major city in Texas. Its parent bank holding company is Texas Capital Bancshares. It also operates an online-only banking division, Bask Bank.
ESPR vs TCBI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $324.0M |
| Net Profit | — | $73.8M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | 22.8% |
| Revenue YoY | 143.7% | 15.5% |
| Net Profit YoY | — | 56.8% |
| EPS (diluted) | $0.32 | $1.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $324.0M | ||
| Q4 25 | $168.4M | $327.5M | ||
| Q3 25 | $87.3M | $340.4M | ||
| Q2 25 | $82.4M | $307.5M | ||
| Q1 25 | $65.0M | $280.5M | ||
| Q4 24 | $69.1M | $229.6M | ||
| Q3 24 | $51.6M | $125.3M | ||
| Q2 24 | $73.8M | $267.0M |
| Q1 26 | — | $73.8M | ||
| Q4 25 | — | $100.7M | ||
| Q3 25 | $-31.3M | $105.2M | ||
| Q2 25 | $-12.7M | $77.3M | ||
| Q1 25 | $-40.5M | $47.0M | ||
| Q4 24 | — | $71.0M | ||
| Q3 24 | $-29.5M | $-61.3M | ||
| Q2 24 | $-61.9M | $41.7M |
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 40.4% | ||
| Q3 25 | -11.4% | 40.5% | ||
| Q2 25 | 8.6% | 33.2% | ||
| Q1 25 | -34.0% | 21.6% | ||
| Q4 24 | -6.4% | 40.7% | ||
| Q3 24 | -31.0% | -63.8% | ||
| Q2 24 | 3.5% | 21.9% |
| Q1 26 | — | 22.8% | ||
| Q4 25 | — | 30.7% | ||
| Q3 25 | -35.9% | 30.9% | ||
| Q2 25 | -15.4% | 25.2% | ||
| Q1 25 | -62.2% | 16.8% | ||
| Q4 24 | — | 30.9% | ||
| Q3 24 | -57.2% | -48.9% | ||
| Q2 24 | -83.9% | 15.6% |
| Q1 26 | — | $1.56 | ||
| Q4 25 | $0.32 | $2.11 | ||
| Q3 25 | $-0.16 | $2.18 | ||
| Q2 25 | $-0.06 | $1.58 | ||
| Q1 25 | $-0.21 | $0.92 | ||
| Q4 24 | $-0.14 | $1.43 | ||
| Q3 24 | $-0.15 | $-1.41 | ||
| Q2 24 | $-0.33 | $0.80 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | — |
| Total DebtLower is stronger | — | $878.3M |
| Stockholders' EquityBook value | $-302.0M | $3.6B |
| Total Assets | $465.9M | $33.5B |
| Debt / EquityLower = less leverage | — | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — |
| Q1 26 | — | $878.3M | ||
| Q4 25 | — | $620.6M | ||
| Q3 25 | — | $620.4M | ||
| Q2 25 | — | $620.3M | ||
| Q1 25 | — | $660.5M | ||
| Q4 24 | — | $660.3M | ||
| Q3 24 | — | $660.2M | ||
| Q2 24 | — | $660.0M |
| Q1 26 | — | $3.6B | ||
| Q4 25 | $-302.0M | $3.6B | ||
| Q3 25 | $-451.4M | $3.6B | ||
| Q2 25 | $-433.5M | $3.5B | ||
| Q1 25 | $-426.2M | $3.4B | ||
| Q4 24 | $-388.7M | $3.4B | ||
| Q3 24 | $-370.2M | $3.4B | ||
| Q2 24 | $-344.2M | $3.2B |
| Q1 26 | — | $33.5B | ||
| Q4 25 | $465.9M | $31.5B | ||
| Q3 25 | $364.0M | $32.5B | ||
| Q2 25 | $347.1M | $31.9B | ||
| Q1 25 | $324.0M | $31.4B | ||
| Q4 24 | $343.8M | $30.7B | ||
| Q3 24 | $314.1M | $31.6B | ||
| Q2 24 | $352.3M | $29.9B |
| Q1 26 | — | 0.24× | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.19× | ||
| Q4 24 | — | 0.20× | ||
| Q3 24 | — | 0.20× | ||
| Q2 24 | — | 0.21× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $360.2M | ||
| Q3 25 | $-4.3M | $166.3M | ||
| Q2 25 | $-31.4M | $63.0M | ||
| Q1 25 | $-22.6M | $368.0K | ||
| Q4 24 | $-35.0M | $480.1M | ||
| Q3 24 | $-35.3M | $332.8M | ||
| Q2 24 | $-7.2M | $33.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $347.6M | ||
| Q3 25 | — | $161.3M | ||
| Q2 25 | — | $57.5M | ||
| Q1 25 | — | $-2.0M | ||
| Q4 24 | — | $415.2M | ||
| Q3 24 | $-35.5M | $317.6M | ||
| Q2 24 | $-7.3M | $11.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 106.1% | ||
| Q3 25 | — | 47.4% | ||
| Q2 25 | — | 18.7% | ||
| Q1 25 | — | -0.7% | ||
| Q4 24 | — | 180.9% | ||
| Q3 24 | -68.7% | 253.4% | ||
| Q2 24 | -9.9% | 4.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 3.8% | ||
| Q3 25 | 0.0% | 1.5% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.0% | 0.9% | ||
| Q4 24 | 0.0% | 28.2% | ||
| Q3 24 | 0.3% | 12.1% | ||
| Q2 24 | 0.1% | 8.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.58× | ||
| Q3 25 | — | 1.58× | ||
| Q2 25 | — | 0.81× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 6.76× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
TCBI
Segment breakdown not available.
